Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zai Lab Limited (ZLAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures related to its American Depositary Shares listed on the Nasdaq Global Market. Zai Lab is a research-based, commercial-stage biopharmaceutical company based in China and the United States, focused on oncology, immunology, neuroscience, and infectious disease. Its SEC filings offer detailed information on financial performance, risk factors, capital structure, and key corporate agreements.
Through this page, users can review Zai Lab’s current reports on Form 8-K, which have covered topics such as quarterly financial results and the entry into a material definitive agreement for a renminbi-denominated revolving credit facility to support working capital needs in mainland China. These filings also describe how certain information, including earnings press releases furnished as exhibits, is treated for purposes of the Securities Exchange Act of 1934.
In addition to 8-Ks, investors can use this page as a starting point to locate Zai Lab’s annual and other periodic reports filed with the SEC, which discuss its dual-engine strategy, commercial portfolio in China, and global research and development programs. For a biopharmaceutical company like Zai Lab, these documents are important for understanding product revenue sources, R&D investment, licensing arrangements for medicines such as VYVGART, NUZYRA, ZEJULA, AUGTYRO, and COBENFY, and the financial implications of its pipeline.
Stock Titan enhances the raw filing data with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as new credit facilities, changes in operations, or significant clinical and commercial milestones referenced in the filings. Real-time updates from EDGAR, combined with organized access to forms including 8-K and other SEC documents, allow users to monitor ZLAB’s regulatory reporting and corporate actions efficiently.
ZLAB filed a Form 144 reporting a proposed sale of 5,576 American Depositary Shares and recent dispositions by Ying Du.
The filing lists 5,576 ADS tied to Restricted Stock Vesting with an issuer designation dated 04/01/2026. It also records multiple past sales by Ying Du: four sales of 50,000 ADS on 03/04/2026, 03/05/2026, 03/06/2026, and 03/09/2026, and 1,067 ADS on 03/11/2026, each with reported gross proceeds shown alongside.
ZLAB filed a Form 144 reporting a proposed sale of 9,614 American Depositary Shares tied to restricted stock vesting on 04/01/2026. The notice lists Fidelity Brokerage Services LLC as the broker and shows an aggregate dollar amount of $196,030.42. The filing also discloses 1,966 ADS sold on 03/13/2026 as sales in the past three months.
ZLAB reporting person filed a Form 144 reporting an intended sale of 4,194 American Depositary Shares. The filing lists the 4,194 ADS as Restricted Stock Vesting with an effective date of 04/01/2026 and indicates the shares are connected to compensation.
The filing also discloses prior sales by Frazor T. Edmondson: 15,569 ADS sold on 03/05/2026 for $296,745.14, and 1,281 ADS sold on 03/13/2026 for $23,862.72.
ZLAB affiliate filed a Form 144 to sell up to 5,199 American Depositary Shares following restricted stock vesting. The filing lists the ADS as vested on 04/01/2026 with the broker-dealer Fidelity Brokerage Services LLC. The filing also shows a prior sale of 1,703 ADS on 03/13/2026.
Zai Lab Ltd director Richard Gaynor bought 1,731 American Depositary Shares in an open‑market transaction at $18.91 per ADS. After this purchase, he directly holds 56,630 ADS. The trade was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 16, 2025.
Zai Lab Ltd reported that officer Joshua L. Smiley received new equity awards and completed routine vesting and tax-related sales. On March 4, 2026, he was granted 103,950 stock options with an exercise price of $19.27 per ADS and 33,783 restricted share units (RSUs), each RSU representing one American Depositary Share (ADS). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service. On March 12, 2026, 6,388 RSUs vested and were settled in ADSs, and on March 13, 2026, 1,966 ADSs were sold at $18.628 per ADS automatically to cover taxes. After these transactions, Smiley directly holds 91,026 ADSs, along with remaining RSU and option awards scheduled to vest over time.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported multiple equity compensation moves. On March 4, 2026, he received stock options for 83,160 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring on March 4, 2036, plus 27,027 Restricted Share Units (RSUs). Both awards vest in equal annual installments over four years beginning in 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs were exercised into the same number of ADSs, and on March 13, 2026 he sold 1,281 ADSs at $18.628 per ADS. Footnotes state these ADSs were sold automatically to cover taxes upon vesting of RSUs. After these transactions, he directly holds 6,494 ADSs.
Zai Lab Ltd Chief Financial Officer Yajing Chen received new equity compensation and reported related share activity. On March 4, 2026, Chen was granted 83,160 stock options with an exercise price of $19.27 per American Depositary Share (ADS), expiring on March 4, 2036, and 27,027 Restricted Share Units (RSUs). These options and RSUs vest in equal annual installments over four years beginning on March 4, 2027, subject to continuous service.
On March 12, 2026, 4,258 RSUs vested and converted into the same number of ADSs, and on March 13, 2026, 1,703 ADSs were sold at $18.628 per ADS. According to the footnotes, these ADSs were sold automatically to cover taxes due upon RSU vesting, rather than as a discretionary open-market sale. After these transactions, Chen held 19,999 ADSs directly.
Zai Lab Ltd officer Rafael Amado reported compensation-related equity activity and a small share sale. He received stock options for 103,950 American Depositary Shares (ADSs) at an exercise price of $19.27 per ADS, expiring in 2036, and 33,783 Restricted Share Units (RSUs) linked to ADSs.
On March 12, 2026, 5,323 RSUs were exercised into the same number of ADSs, increasing his direct ADS holdings. On March 13, 2026, he sold 2,957 ADSs at $18.628 per ADS, with a footnote stating these ADSs were sold automatically to cover taxes upon RSU vesting. After these transactions, he directly held 44,757 ADSs and 15,971 RSUs. Each ADS represents ten ordinary shares.
Zai Lab Ltd reported new equity awards to Chairperson and CEO Ying Du. On March 11, 2026, Du received stock options for 353,430 American Depositary Shares (ADSs) with an exercise price of 19.34 per ADS, expiring on March 11, 2036.
The filing also shows a grant of 32,419 Restricted Share Units (RSUs), each representing one ADS. Both the options and RSUs vest in equal annual installments over four years beginning on March 11, 2027, subject to continuous service. Each ADS represents ten ordinary shares of Zai Lab.